Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Notable Labs, Ltd.: Amendments to the Amended and Restated Articles of Association to effect a reverse share split, increase registered share capital, change company name, and modify quorum requirements (effective 2023-10-16).
- Change
- charter amendment
- Effective
- 2023-10-16
Exact text from the filing
On October 16, 2023, immediately prior to the closing of the Merger, the Company filed an amendment to the Articles with the Israeli Registrar of Companies reflecting the Reverse Share Split (including an increase in par value to NIS 0.35 per Ordinary Share), the Share Capital Increase (such that the Company has 34,285,714 authorized Ordinary Shares and NIS 12,000,000 of registered share capital) and the Name Change.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Notable Labs, Ltd. underwent a change of control involving Notable Labs, Inc. (closed 2023-10-16).
- Action
- change of control
- Counterparty
- Notable Labs, Inc.
- Closing
- 2023-10-16
Exact text from the filing
On October 16, 2023, Notable Labs, Ltd., formerly known as "Vascular Biogenics Ltd." (the "Company" or "VBL"), completed its business combination with Notable Labs, Inc. ("Notable") and Vibrant Merger Sub, Inc., a wholly-owned subsidiary of the Company ("Merger Sub") in accordance with the terms of the Agreement and Plan of Merger, dated as of February 22, 2023 (the "Merger Agreement"), by and among the Company, Notable and Merger Sub.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Notable Labs, Ltd. completed a disposition involving Immunewalk Therapeutics Inc. for an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to $4.75 million upon the achievement of clinical and commercial (closed 2023-10-16).
- Action
- disposition
- Counterparty
- Immunewalk Therapeutics Inc.
- Consideration
- an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to $4.75 million upon the achievement of clinical and commercial
- Closing
- 2023-10-16
Exact text from the filing
of October 1, 2023, between the Company and Immunewalk (the “Asset Purchase Agreement”). Under the Asset Purchase Agreement, Immunewalk agreed to pay an upfront cash payment of $250,000 to the Company at the closing and additional payments of up to $4.75 million upon the achievement of clinical and commercial milestones by Immunewalk, its Affiliates or Licensees.
View on SEC.gov